FDA inspection citations: Staska Pharmaceuticals, Inc. (3 observations)
FDA cites Staska Pharmaceuticals for quality and sterility issues.
What changed & why it matters
Med Spa Radar recorded an FDA inspection citation at the federal level, dated February 20, 2026, in the GLP-1 Compounding category.
An inspection citation records what FDA investigators observed at a drug or biologic facility. For an aesthetic practice, the question a citation raises is supplier due-diligence: a cited compounder or outsourcing facility is one whose FDA inspection history is now on the public record.
- Type
- FDA Inspection Citation
- Jurisdiction
- Federal
- Category
- GLP-1 Compounding
- Recorded
- February 20, 2026
What this means for your specific practice — the exact step to take, the deadline to calendar, or the supplier detail to check — is in the member "what to do" below. This page is the free record of what changed and why it matters.
Firm inspection: Official Action Indicated
This firm’s most recent FDA inspection was classified Official Action Indicated (OAI) — FDA’s most serious outcome, signaling significant violations.
Source: FDA Data Dashboard inspection classifications (most recent, by firm FEI).
What to do
Free weekly Brief
Get the changes that matter in plain English, every week — and be alerted when the rules move. No charge.
Members get the full “what to do” on every alert — in real time, for your states. Become a member →
FDA Inspection Citation · primary source ↗
Related alerts
- FDA recall (Class II): Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, Ks 66061,…
- FDA recall (Class II): Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy
- FDA recall (Class II): Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, …
- FDA recall (Class II): Tirzepatide Injections, 30mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewo…
- FDA recall (Class II): Wegovy (Semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880…
- FDA recall (Class II): Wegovy (Semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx …
Monitoring, not legal advice.